Literature DB >> 10438870

Primary human immunodeficiency virus type 2 (HIV-2) isolates infect CD4-negative cells via CCR5 and CXCR4: comparison with HIV-1 and simian immunodeficiency virus and relevance to cell tropism in vivo.

J D Reeves1, S Hibbitts, G Simmons, A McKnight, J M Azevedo-Pereira, J Moniz-Pereira, P R Clapham.   

Abstract

Cell surface receptors exploited by human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) for infection are major determinants of tropism. HIV-1 usually requires two receptors to infect cells. Gp120 on HIV-1 virions binds CD4 on the cell surface, triggering conformational rearrangements that create or expose a binding site for a seven-transmembrane (7TM) coreceptor. Although HIV-2 and SIV strains also use CD4, several laboratory-adapted HIV-2 strains infect cells without CD4, via an interaction with the coreceptor CXCR4. Moreover, the envelope glycoproteins of SIV of macaques (SIV(MAC)) can bind to and initiate infection of CD4(-) cells via CCR5. Here, we show that most primary HIV-2 isolates can infect either CCR5(+) or CXCR4(+) cells without CD4. The efficiency of CD4-independent infection by HIV-2 was comparable to that of SIV, but markedly higher than that of HIV-1. CD4-independent HIV-2 strains that could use both CCR5 and CXCR4 to infect CD4(+) cells were only able to use one of these receptors in the absence of CD4. Our observations therefore indicate (i) that HIV-2 and SIV envelope glycoproteins form a distinct conformation that enables contact with a 7TM receptor without CD4, and (ii) the use of CD4 enables a wider range of 7TM receptors to be exploited for infection and may assist adaptation or switching to new coreceptors in vivo. Primary CD4(-) fetal astrocyte cultures expressed CXCR4 and supported replication by the T-cell-line-adapted ROD/B strain. Productive infection by primary X4 strains was only triggered upon treatment of virus with soluble CD4. Thus, many primary HIV-2 strains infect CCR5(+) or CXCR4(+) cell lines without CD4 in vitro. CD4(-) cells that express these coreceptors in vivo, however, may still resist HIV-2 entry due to insufficient coreceptor concentration on the cell surface to trigger fusion or their expression in a conformation nonfunctional as a coreceptor. Our study, however, emphasizes that primary HIV-2 strains carry the potential to infect CD4(-) cells expressing CCR5 or CXCR4 in vivo.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10438870      PMCID: PMC104307          DOI: 10.1128/JVI.73.9.7795-7804.1999

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  88 in total

1.  Identification of two neutralizing and 8 non-neutralizing epitopes on simian immunodeficiency virus envelope using monoclonal antibodies.

Authors:  K A Kent; E Rud; T Corcoran; C Powell; C Thiriart; C Collignon; E J Stott
Journal:  AIDS Res Hum Retroviruses       Date:  1992-06       Impact factor: 2.205

Review 2.  Vaccine studies with the 32H reisolate of SIVmac251: an overview.

Authors:  M Cranage; J Stott; K Mills; T Ashworth; F Taffs; G Farrar; L Chan; M Dennis; P Putkonen; G Biberfeld
Journal:  AIDS Res Hum Retroviruses       Date:  1992-08       Impact factor: 2.205

3.  Usage of the coreceptors CCR-5, CCR-3, and CXCR-4 by primary and cell line-adapted human immunodeficiency virus type 2.

Authors:  N Sol; F Ferchal; J Braun; O Pleskoff; C Tréboute; I Ansart; M Alizon
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Human immunodeficiency virus type 2 infection and fusion of CD4-negative human cell lines: induction and enhancement by soluble CD4.

Authors:  P R Clapham; A McKnight; R A Weiss
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

5.  Spread of HIV-2 in India.

Authors:  H Rübsamen-Waigmann; H V Briesen; J K Maniar; P K Rao; C Scholz; A Pfützner
Journal:  Lancet       Date:  1991-03-02       Impact factor: 79.321

6.  Human infection by genetically diverse SIVSM-related HIV-2 in west Africa.

Authors:  F Gao; L Yue; A T White; P G Pappas; J Barchue; A P Hanson; B M Greene; P M Sharp; G M Shaw; B H Hahn
Journal:  Nature       Date:  1992-08-06       Impact factor: 49.962

7.  GLVR1, a receptor for gibbon ape leukemia virus, is homologous to a phosphate permease of Neurospora crassa and is expressed at high levels in the brain and thymus.

Authors:  S V Johann; J J Gibbons; B O'Hara
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

8.  HIV-2 antibodies in serum samples from Maharashtra state.

Authors:  S Kulkarni; M Thakar; J Rodrigues; K Banerjee
Journal:  Indian J Med Res       Date:  1992-09       Impact factor: 2.375

9.  A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells.

Authors:  J P Moore; Q J Sattentau; P J Klasse; L C Burkly
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

10.  Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4.

Authors:  D Schols; S Struyf; J Van Damme; J A Esté; G Henson; E De Clercq
Journal:  J Exp Med       Date:  1997-10-20       Impact factor: 14.307

View more
  55 in total

Review 1.  Receptors and entry cofactors for retroviruses include single and multiple transmembrane-spanning proteins as well as newly described glycophosphatidylinositol-anchored and secreted proteins.

Authors:  J Overbaugh; A D Miller; M V Eiden
Journal:  Microbiol Mol Biol Rev       Date:  2001-09       Impact factor: 11.056

2.  Determination of essential amino acids involved in the CD4-independent tropism of the X4 human immunodeficiency virus type 1 m7NDK isolate: role of potential N glycosylations in the C2 and V3 regions of gp120.

Authors:  J Dumonceaux; C Goujon; V Joliot; P Briand; U Hazan
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

Review 3.  Emerging drug targets for antiretroviral therapy.

Authors:  Jacqueline D Reeves; Andrew J Piefer
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote.

Authors:  Paul R Gorry; Rebecca L Dunfee; Megan E Mefford; Kevin Kunstman; Tom Morgan; John P Moore; John R Mascola; Kristin Agopian; Geoffrey H Holm; Andrew Mehle; Joann Taylor; Michael Farzan; Hui Wang; Philip Ellery; Samantha J Willey; Paul R Clapham; Steven M Wolinsky; Suzanne M Crowe; Dana Gabuzda
Journal:  Virology       Date:  2007-01-18       Impact factor: 3.616

Review 5.  HIV and the chemokine system: 10 years later.

Authors:  Paolo Lusso
Journal:  EMBO J       Date:  2006-01-26       Impact factor: 11.598

6.  Simian immunodeficiency viruses of diverse origin can use CXCR4 as a coreceptor for entry into human cells.

Authors:  S M Owen; S Masciotra; F Novembre; J Yee; W M Switzer; M Ostyula; R B Lal
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

7.  Development of antibody-modified chitosan nanoparticles for the targeted delivery of siRNA across the blood-brain barrier as a strategy for inhibiting HIV replication in astrocytes.

Authors:  Jijin Gu; Karam Al-Bayati; Emmanuel A Ho
Journal:  Drug Deliv Transl Res       Date:  2017-08       Impact factor: 4.617

8.  CD4-independent use of Rhesus CCR5 by human immunodeficiency virus Type 2 implicates an electrostatic interaction between the CCR5 N terminus and the gp120 C4 domain.

Authors:  G Lin; B Lee; B S Haggarty; R W Doms; J A Hoxie
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

9.  Interferon-alpha mediates restriction of human immunodeficiency virus type-1 replication in primary human macrophages at an early stage of replication.

Authors:  Kelly M Cheney; Áine McKnight
Journal:  PLoS One       Date:  2010-10-20       Impact factor: 3.240

10.  Biological analysis of human immunodeficiency virus type 1 R5 envelopes amplified from brain and lymph node tissues of AIDS patients with neuropathology reveals two distinct tropism phenotypes and identifies envelopes in the brain that confer an enhanced tropism and fusigenicity for macrophages.

Authors:  Paul J Peters; Jayanta Bhattacharya; Samantha Hibbitts; Matthias T Dittmar; Graham Simmons; Jeanne Bell; Peter Simmonds; Paul R Clapham
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.